Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication.
Hum Vaccin Immunother
; 14(8): 2053-2057, 2018.
Article
em En
| MEDLINE
| ID: mdl-29617191
ABSTRACT
Alpha-galactosylceramide (αGalCer) is a glycolipid derived from a marine sponge that is a potent activator of both mouse and human invariant natural killer T (iNKT) cells. For that reason, αGalCer is a promising vaccine adjuvant that has been shown to improve both humoral and cellular immunity when co-administered with various vaccines, including candidate vaccines for biodefense. In the current study, we tested the effectiveness of αGalCer as an adjuvant for the clinically-relevant ricin toxin subunit vaccine, RiVax. αGalCer had a potent adjuvant effect, as shown by a rapid onset of anti-ricin IgG titers, accelerated development of serum toxin-neutralizing activity, and enhanced protection from lethal ricin challenge in a mouse model. These results underscore the potential of αGalCer to augment the protective immune response to a vaccine designed to counteract ricin toxin, a fast-acting biothreat agent.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Intoxicação
/
Ricina
/
Vacinas
/
Adjuvantes Imunológicos
/
Galactosilceramidas
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article